ABBV vs TMO
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | ABBV | TMO | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $264.96 | $629.27 | |
| Market cap as of 2026-08-24 | $468.2B | $232.7B | |
| P/E as of 2026-08-24 | 70.24 | 31.95 | TMO lower |
| PEG as of 2026-08-24 | 6.59 | 3.39 | TMO lower |
| Net margin as of 2026-08-24 | +9.8% | +15.0% | TMO higher |
| Gross margin as of 2026-08-24 | +72.8% | +40.9% | ABBV higher |
| Operating margin as of 2026-08-24 | +26.2% | +17.6% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | +13.3% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | +6.3% | TMO higher |
| Debt / equity as of 2026-08-24 | 49.22 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | +7.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -0.3% | ABBV higher |
| Dividend yield as of 2026-08-24 | +4.5% | +0.3% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.22 | 0.90 | |
| 1-year return as of 2026-08-21 close | +26.5% | +30.1% | TMO higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.